Zealand Pharma finds all patients for phase III study

A total of 108 patients have been enrolled in Zealand Pharma's crucial trial of glepaglutide as a treatment of short bowel syndrome.

Photo: Zealand Pharma / PR

Biotech company Zealand Pharma has recruited all 108 patients required for a phase III study of its drug candidate glepaglutide, which is meant to treat short bowel syndrome, the company announces in a press release.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs